搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Chaetomium globosum DNA-directed RNA polymerase III subunit RPC3 (RPC82), partial CSB-YP641290CHI
CSB-EP641290CHI
CSB-BP641290CHI
CSB-MP641290CHI
CSB-EP641290CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum Autophagy-related protein 8 (ATG8) CSB-YP641291CHI
CSB-EP641291CHI
CSB-BP641291CHI
CSB-MP641291CHI
CSB-EP641291CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum ATP-dependent RNA helicase FAL1 (FAL1) CSB-YP641292CHI
CSB-EP641292CHI
CSB-BP641292CHI
CSB-MP641292CHI
CSB-EP641292CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum ATPase GET3 (GET3) CSB-YP641293CHI
CSB-EP641293CHI
CSB-BP641293CHI
CSB-MP641293CHI
CSB-EP641293CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum Autophagy-related protein 2 (ATG2), partial CSB-YP641294CHI
CSB-EP641294CHI
CSB-BP641294CHI
CSB-MP641294CHI
CSB-EP641294CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum DNA damage-inducible protein 1 (DDI1) CSB-YP641295CHI
CSB-EP641295CHI
CSB-BP641295CHI
CSB-MP641295CHI
CSB-EP641295CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum Protein STU1 (STU1), partial CSB-YP641296CHI
CSB-EP641296CHI
CSB-BP641296CHI
CSB-MP641296CHI
CSB-EP641296CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum Protein CLP1 (CLP1) CSB-YP641297CHI
CSB-EP641297CHI
CSB-BP641297CHI
CSB-MP641297CHI
CSB-EP641297CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum Mediator of RNA polymerase II transcription subunit 4 (MED4) CSB-YP641298CHI
CSB-EP641298CHI
CSB-BP641298CHI
CSB-MP641298CHI
CSB-EP641298CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum Chromosome segregation in meiosis protein 3 (CSM3) CSB-YP641299CHI
CSB-EP641299CHI
CSB-BP641299CHI
CSB-MP641299CHI
CSB-EP641299CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum Assembly factor CBP4 (CBP4), partial CSB-YP641300CHI
CSB-EP641300CHI
CSB-BP641300CHI
CSB-MP641300CHI
CSB-EP641300CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum rRNA-processing protein EFG1 (EFG1) CSB-YP641301CHI
CSB-EP641301CHI
CSB-BP641301CHI
CSB-MP641301CHI
CSB-EP641301CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum ATP-dependent RNA helicase DBP2 (DBP2), partial CSB-YP641302CHI
CSB-EP641302CHI
CSB-BP641302CHI
CSB-MP641302CHI
CSB-EP641302CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum Mediator of RNA polymerase II transcription subunit 10 (NUT2) CSB-YP641303CHI
CSB-EP641303CHI
CSB-BP641303CHI
CSB-MP641303CHI
CSB-EP641303CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum Histone-lysine N-methyltransferase, H3 lysine-79 specific (DOT1), partial CSB-YP641304CHI
CSB-EP641304CHI
CSB-BP641304CHI
CSB-MP641304CHI
CSB-EP641304CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum Patatin-like phospholipase domain-containing protein CHGG_02900 (CHGG_02900), partial CSB-YP641305CHI
CSB-EP641305CHI
CSB-BP641305CHI
CSB-MP641305CHI
CSB-EP641305CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum Plasma membrane proteolipid 3 (PMP3), partial CSB-YP641306CHI
CSB-EP641306CHI
CSB-BP641306CHI
CSB-MP641306CHI
CSB-EP641306CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum Pescadillo homolog (NOP7), partial CSB-YP641307CHI
CSB-EP641307CHI
CSB-BP641307CHI
CSB-MP641307CHI
CSB-EP641307CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum tRNA-dihydrouridine (47) synthase [NAD (P) (+)] (DUS3), partial CSB-YP641308CHI
CSB-EP641308CHI
CSB-BP641308CHI
CSB-MP641308CHI
CSB-EP641308CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chaetomium globosum DNA replication complex GINS protein SLD5 (SLD5) CSB-YP641309CHI
CSB-EP641309CHI
CSB-BP641309CHI
CSB-MP641309CHI
CSB-EP641309CHI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>